Physician profile
Stephen Lakner
NPI 1043295389
$1,763.49
in general payments reported to CMS, 2019-2025
27 companies · $258 in 2025
The $258 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $600 · 2020: $54.46 · 2021: $252 · 2022: $203 · 2023: $321 · 2024: $75.52 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $654.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $350.72 | 2019-2023 | |
| Astellas Pharma US INC | $193.59 | 2019-2025 | Veozah |
| Aspira Women'S Health INC | $160.57 | 2019-2021 | |
| Allergan, INC. | $109.80 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $104.72 | 2019-2022 | |
| Myovant Sciences INC. | $84.03 | 2021-2022 | |
| Therapeuticsmd, INC. | $81.63 | 2019-2022 | |
| Smith+Nephew, INC. | $78.30 | 2019 | |
| Coopersurgical, INC. | $76.19 | 2022-2023 | Paragard T 380a |
| Sumitomo Pharma America, INC. | $72.77 | 2023-2025 | Myfembree, Gemtesa |
| Exact Sciences Corporation | $61.72 | 2023 | Cologuard Collection Kit |
| Sage Therapeutics, LLC | $51.02 | 2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $38.87 | 2023-2025 | |
| Gilead Sciences, INC. | $33.62 | 2025 | |
| Organon LLC | $33.55 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $30.36 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $26.11 | 2023 | Gardasil 9 |
| Shield Therapeutics INC | $25.82 | 2025 | |
| Daiichi Sankyo INC. | $23.79 | 2019 | |
| Hologic Sales and Service, LLC | $22.70 | 2022 | |
| Amag Pharmaceuticals, INC. | $20.72 | 2019 | |
| Distalmotion US | $20.25 | 2025 | Dexter L6 Robot |
| Exeltis, USA INC. | $20.03 | 2022 | |
| Supernus Pharmaceuticals, INC. | $16.31 | 2025 | Qelbree |
| Evofem Biosciences, INC. | $15.14 | 2021 | |
| Olympus America INC. | $11.16 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Lakner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.